Loading...
•
Sep 30, 2021
Y-mAbs Q3 2021 Earnings Report
Reported third quarter financial results and recent corporate developments.
Key Takeaways
Y-mAbs reported net revenues of $9.0 million for the quarter ended September 30, 2021 related to sales of DANYELZA. The company ended the quarter with a cash balance of $215.7 million.
DANYELZA commercialization throughout the U.S continue to impress, as sales volume ex-MSK increased by 49% quarter over quarter.
Resubmission of the omburtamab BLA is progressing as planned and the company has requested a pre-BLA meeting with the aim of initiating a resubmission the BLA shortly thereafter.
The company plans to submit the IND for its GD2-SADA construct in December.
The company ended the quarter with a cash balance of $215.7 million.
Revenue by Geographic Location
Forward Guidance
The company plans to submit the IND for its GD2-SADA construct in December, and they expect to submit at least one SADA IND per year, partly from their own pipeline of SADA constructs, and partly through one or more partnerships, which they expect to enter into during the next 6-12 months.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...